Cryptococcal meningitis in HIV-infected patients
- 63 Downloads
Cryptococcosis is a fungal infection that is potentially deadly for and common among AIDS patients, in the United States and worldwide. Subacute meningitis and meningoencephalitis are typical, clinically. This article will review relevant aspects of cryptococcal meningitis in AIDS, focusing on the most recent information pertaining to pathogenesis, epidemiology, clinical syndromes, and treatment of this devastating disease.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 15.Mocroft A, Sabin CA, Youle M, et al.: Changes in AIDS-defining illnesses in a London Clinic, 1987–1998. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:401–407.Google Scholar
- 19.Feldmeser M, Harris C, Reichberg S, Khan S, Casadevall A. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996, 23:827–830.Google Scholar
- 25.Saag MS, Cloud GA, Graybill, JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999, 28:291–296. This randomized comparison of fluconazole and itraconazole as suppressive therapy was stopped early because of the striking superiority of fluconazole. An interesting analysis suggested that the use of flucytosine in the initial treatment regimen was associated with a lower risk of relapse. Although considerable caution is needed in interpreting these data (there may be considerable selection bias), they are consistent with the hypothesis that more aggressive initial therapy (including rapid sterilization of the CSF) improves long-term outcome (see also reference 27).PubMedGoogle Scholar
- 27.Robinson PA, Bauer M, Leal MA, et al.: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82–92. This retrospective analysis of 236 patients, all treated at the same center, reported 12% acute mortality and 26% mortality at 10 weeks. High CSF cryptococcal antigen titers, low CD4 count and low serum albumin levels were predictive of a poor outcome. Higher doses of amphotericin were associated with more rapid sterilization of the CSF.PubMedGoogle Scholar
- 31.Hamill RJ, Sobel J, el-Sadr W, et al.: Randomized double blind trial of Ambisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. [abstract]. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999.Google Scholar
- 33.Graybill JR, Sobel J, Saag M, et al.: Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis. Clin Infect Dis 2000, 30:47–54. This important study highlights the fact that high opening pressure in the CSF (> 250 mm of H2O) at the time of diagnosis of cryptococcal meningitis is associated with more advanced disease, and an increased risk of death. Further, a reduction in opening pressure during treatment is associated with clinical response. The authors recommend large volume drainage for all patients with high opening pressures.PubMedCrossRefGoogle Scholar
- 41.McKinsey DS, Wheat LJ, Cloud GA, et al.: Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebocontrolled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:1049–1056. Itraconazole effectively prevented both histoplasmosis and cryptococcosis in this study, and could be regarded as the preferred prophylactic agent for anti-fungal prophyaxis in patients living in the endemic area.PubMedGoogle Scholar
- 42.USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999, 48(RR10):1–59.Google Scholar